Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, will participate in the virtual Cowen 42nd Annual Health Care Conference from March 7-9, 2022.

Rhea-AI Summary

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, will participate in the virtual Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Brian Sullivan, the CEO, will join the "Breast Cancer" panel session on March 9 at 2:10 p.m. ET. Investors can access a live webcast of the event via this link or through the company's website, with a replay available post-event.

Celcuity focuses on developing targeted therapies and companion diagnostics to improve cancer treatment.

Argus Session date unavailable

+1.86% session move Open Argus

Details

News Market Reaction – CELC

The recorded move for CELC in the trading session of this news was +1.86%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced its participation in the virtual Cowen 42nd Annual Health Care Conference to be held March 7-9, 2022. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to participate in the "Breast Cancer" corporate panel session at 2:10 p.m. ET on Wednesday, March 9, 2022.

A live webcast of the panel session will be available using this weblink: https://wsw.com/webcast/cowen108/panel23/2324601. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/690965/Celcuity-to-Participate-in-the-Cowen-42nd-Annual-Health-Care-Conference

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Celcuity participating in the Cowen 42nd Annual Health Care Conference?

Celcuity will participate in the conference from March 7-9, 2022.

Who will represent Celcuity at the Cowen Conference?

Brian Sullivan, the Chairman and CEO of Celcuity, will represent the company.

What time is Celcuity's panel session at the Cowen Conference?

The panel session will take place on March 9, 2022, at 2:10 p.m. ET.

How can I watch the webcast of Celcuity's Cowen Conference panel?

You can watch the live webcast using this link or through the Investors section of Celcuity's website.

What is Celcuity's focus as a biotechnology company?

Celcuity focuses on developing molecularly targeted therapies and companion diagnostics for cancer treatment.